A Phase 2 interventional study of Bomedemstat in Polycythemia Vera, sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA). Completed at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies in Polycythemia Vera with a site in United States — 22 open to participants now, 34 under way, 7 of them phase 3. Polycythemia Vera · United States.
Among the 179 studies in Polycythemia Vera with a site in United States, this one is the 111th largest by enrollment of the 150 interventional ones that give a count, is one of 3 that started in 2023, is one of 68 in phase 2, and was the 161st registered.
278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.
Browse Polycythemia Vera studies →22 of the 179 studies in Polycythemia Vera with a site in United States are open now. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Canada, Israel
Ages 18+
Massachusetts General Hospital · Sites in United States
Healthy volunteers
Ono Pharmaceutical Co., Ltd. · Sites in United States, Australia, Austria and 6 more countries
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 61 · Phase 2 89 · Phase 3 20
First in 1992; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 52 across 204 interventional studies indexed under Polycythemia Vera.
Median enrollment 40 across the 150 interventional studies, 678 across the 15 observational. Of the 135 that completed or were terminated, 54 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 179 have an industry lead sponsor. The 10 most frequent:
This study is registered under Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Merck & Co., Inc has 3 studies filed under Polycythemia Vera — fewer than ten, so there is no comparison to draw.
9 of the studies in Polycythemia Vera with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT07203768FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSA ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes | 2026-12-31 |
| NCT06063486University of Southern CaliforniaCurcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 179 studies in Polycythemia Vera with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics of the orally administered lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat, in participants with polycythemia vera (PV). At Week 36 of dosing, participants will be assessed for eligibility to receive additional treatment through Week 52. Participants deriving clinical benefit and safely tolerating bomedemstat will qualify for continued treatment at the Investigator's discretion.
With Amendment 3, after all ongoing participants have reached 52 weeks of treatment, eligible participants may transition to a bomedemstat extension study if available. With Amendment 4, all secondary PK and participant reported outcome measures were designated as exploratory.
Per protocol, participants who derived clinical benefit (no progressive disease) and safely tolerated drug may have qualified for enrollment into the bomedemstat extension study (NCT06351631).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive bomedemstat daily for 36 weeks and may qualify for additional treatment through Week 52 if deriving clinical benefit.
Drug: Bomedemstat
Oral capsule
Also known as: MK-3543, IMG-7289
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs are reported.
Time frame: Up to approximately 52 weeks
Number of Participants Who Discontinued Study Intervention Due to AEs
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study intervention due to an AE are reported.
Time frame: Up to approximately 52 weeks
Percentage of Participants With Sustained 12-week Reduction of Hematocrit (Hct) to <45% Without Concomitant Phlebotomy by Week 36
Hematocrit (Hct) was analyzed by taking blood samples from participants at designated time points during the study. Participants were considered responders if they achieved a sustained reduction of Hct to \<45% for 12 weeks (84 calendar days) by Week 36 AND there was no concomitant phlebotomy performed during the sustained reduction. Baseline data was defined as the data most recently collected prior to the first dose. A Clopper-Pearson (exact binomial) two-sided 95% confidence interval for the percentage of responders was presented. The percentage of participants who achieved a sustained 12-week reduction of Hct to \<45% without concomitant phlebotomy at Week 36 are reported.
Time frame: Up to approximately 36 weeks
Duration of Reduction of Hematocrit (Hct) to <45% Without Phlebotomy
Total response duration was defined as the summation of all Hct \<45% response durations, where an individual response duration starts at the timepoint where the Hct \<45% and ends at the first subsequent occurrence of phlebotomy or Hct \>=45%. Hct was analyzed by taking blood samples from participants at designated time points during the study. Duration of reduction of Hct to \<45% without phlebotomy was presented.
Time frame: Up to approximately 22 months
Percentage of Participants With Platelet Count ≤ 450 x 10^9/L by Week 36
Platelet count was analyzed by taking blood samples from participants at designated time points during the study. Participants who enter the study with platelet counts ≤450 X 10\^9/L must achieve an additional on-study platelet count ≤450 X 10\^9/L to be considered responders. A Clopper-Pearson (exact binomial) two-sided 95% confidence interval for the percentage of responders is presented. Baseline data was defined as the data most recently collected prior to the first dose. The percentage of participants who have a platelet count ≤450 X 10\^9/L by week 36 are reported.
Time frame: Up to approximately 36 weeks
Duration of Platelet Count ≤ 450 x 10^9/L
Total response duration was defined as the summation of all platelet ≤450 x 10\^9/L response durations, where an individual response duration starts at the timepoint where platelet count ≤450 x 10\^9/L and ends at the first subsequent occurrence of platelet \>450 x 10\^9/L. Platelet counts were analyzed by taking blood samples from participants at designated time points during the study. The duration of platelet count ≤450 X 10\^9/L in participants are reported.
Time frame: Up to approximately 22 months
Percentage of Participants With White Blood Cell (WBC) Count <10 x 10^9/L by Week 36
WBC count was analyzed by taking blood samples from participants at designated time points during the study. Participants who enter the study with WBC counts \<10 X 10\^9/L must achieve an additional on-study WBC count \<10 X 10\^9/L to be considered responders. A Clopper-Pearson (exact binomial) two-sided 95% confidence interval for the percentage of responders is presented. Baseline data was defined as the data most recently collected prior to the first dose. The percentage of participants who have a WBC count \<10 X 10\^9/L week 36 are reported.
Time frame: Up to approximately 36 weeks
Duration of White Blood Cell (WBC) Count <10 x 10^9/L
Total response duration was defined as the summation of all WBC \<10 x 10\^9/L response durations, where an individual response duration starts at the timepoint when WBC \<10 x 10\^9/L and ends at the first subsequent occurrence of WBC ≥ 10 x 10\^9/L. WBC count was analyzed by taking blood samples from participants at designated time points during the study. The duration of WBC count \<10 X 10\^9/L in participants are reported.
Time frame: Up to approximately 22 months
Number of Participants With Thrombotic Events
Thrombotic events are defined as: new or recurrent acute myocardial infarction; unstable angina; stroke; transient ischemic attack (TIA); deep venous thrombosis (DVT); pulmonary embolism (PE); thrombotic digital ischemia; other thrombotic events such as peripheral limb ischemia or Budd-Chiari syndrome that are assessed to be due to underlying polycythemia vera (PV); other vascular occlusive events such as symptoms of cardiac, abdominal or peripheral limb ischemia supported by objective evidence of vessel disease and/or ischemia. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with thrombotic events are reported.
Time frame: Up to approximately 22 months
Number of Participants With Major Hemorrhagic Events
Hemorrhagic events were defined as: Major Bleeding (MB) Events such as fatal bleeding, and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells; Clinically Relevant Non-Major Bleeding (CRNMB) Events Leading to hospitalization or increased level of care or clinically important, prompting a face-to-face medical evaluation. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with major hemorrhagic events are reported.
Time frame: Up to approximately 22 months
Number of Participants With an Enlarged Spleen at Baseline Who Had a Reduction in Splenic Volume by 36 Weeks
Spleen volume was measured by magnetic resonance imaging (MRI) (or computerized tomography \[CT\] if participant is not a candidate for MRI) of the abdomen according to standard procedures. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with an enlarged spleen at baseline (volume \>450 cm\^3) who achieved any reduction in spleen volume by Week 36 are reported.
Time frame: Up to approximately 36 weeks
Number of Participants With Progressive Disease (PD)
PD was defined as the worsening of Polycythemia Vera (PV) to post-PV myelofibrosis, myelodysplastic syndrome or transformation to acute myeloid leukemia. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with PD are reported.
Time frame: Up to approximately 52 weeks
This study recruited participants with Polycythemia Vera (PV) requiring cytoreduction that have failed at least one standard cytoreductive therapy (failure is the equivalent of resistance or intolerance).
| Milestone | Bomedemstat |
|---|---|
| Started | 20 |
| Completed | 5 |
| Not completed | 15 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Progressive disease | 1 |
| Withdrew: Physician decision | 2 |
| Withdrew: Death | 1 |
| Withdrew: Transition into extension study | 7 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs are reported.
| Participants | Bomedemstat |
|---|---|
| Number of Participants With Adverse Events (AEs) | 20 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study intervention due to an AE are reported.
| Participants | Bomedemstat |
|---|---|
| Number of Participants Who Discontinued Study Intervention Due to AEs | 0 |
Hematocrit (Hct) was analyzed by taking blood samples from participants at designated time points during the study. Participants were considered responders if they achieved a sustained reduction of Hct to \<45% for 12 weeks (84 calendar days) by Week 36 AND there was no concomitant phlebotomy performed during the sustained reduction. Baseline data was defined as the data most recently collected prior to the first dose. A Clopper-Pearson (exact binomial) two-sided 95% confidence interval for the percentage of responders was presented. The percentage of participants who achieved a sustained 12-week reduction of Hct to \<45% without concomitant phlebotomy at Week 36 are reported.
| Percentage of Participants | Bomedemstat |
|---|---|
| Percentage of Participants With Sustained 12-week Reduction of Hematocrit (Hct) to <45% Without Concomitant Phlebotomy by Week 36 | 45.0 (23.1 to 68.5) |
Total response duration was defined as the summation of all Hct \<45% response durations, where an individual response duration starts at the timepoint where the Hct \<45% and ends at the first subsequent occurrence of phlebotomy or Hct \>=45%. Hct was analyzed by taking blood samples from participants at designated time points during the study. Duration of reduction of Hct to \<45% without phlebotomy was presented.
| Months | Bomedemstat |
|---|---|
| Duration of Reduction of Hematocrit (Hct) to <45% Without Phlebotomy | 6.4 (0.3 to 21.2) |
Platelet count was analyzed by taking blood samples from participants at designated time points during the study. Participants who enter the study with platelet counts ≤450 X 10\^9/L must achieve an additional on-study platelet count ≤450 X 10\^9/L to be considered responders. A Clopper-Pearson (exact binomial) two-sided 95% confidence interval for the percentage of responders is presented. Baseline data was defined as the data most recently collected prior to the first dose. The percentage of participants who have a platelet count ≤450 X 10\^9/L by week 36 are reported.
| Percentage of Participants | Bomedemstat |
|---|---|
| Percentage of Participants With Platelet Count ≤ 450 x 10^9/L by Week 36 | 90.0 (68.3 to 98.8) |
Total response duration was defined as the summation of all platelet ≤450 x 10\^9/L response durations, where an individual response duration starts at the timepoint where platelet count ≤450 x 10\^9/L and ends at the first subsequent occurrence of platelet \>450 x 10\^9/L. Platelet counts were analyzed by taking blood samples from participants at designated time points during the study. The duration of platelet count ≤450 X 10\^9/L in participants are reported.
| Months | Bomedemstat |
|---|---|
| Duration of Platelet Count ≤ 450 x 10^9/L | 11.3 (0.0 to 18.1) |
WBC count was analyzed by taking blood samples from participants at designated time points during the study. Participants who enter the study with WBC counts \<10 X 10\^9/L must achieve an additional on-study WBC count \<10 X 10\^9/L to be considered responders. A Clopper-Pearson (exact binomial) two-sided 95% confidence interval for the percentage of responders is presented. Baseline data was defined as the data most recently collected prior to the first dose. The percentage of participants who have a WBC count \<10 X 10\^9/L week 36 are reported.
| Percentage of Participants | Bomedemstat |
|---|---|
| Percentage of Participants With White Blood Cell (WBC) Count <10 x 10^9/L by Week 36 | 75.0 (50.9 to 91.3) |
Total response duration was defined as the summation of all WBC \<10 x 10\^9/L response durations, where an individual response duration starts at the timepoint when WBC \<10 x 10\^9/L and ends at the first subsequent occurrence of WBC ≥ 10 x 10\^9/L. WBC count was analyzed by taking blood samples from participants at designated time points during the study. The duration of WBC count \<10 X 10\^9/L in participants are reported.
| Months | Bomedemstat |
|---|---|
| Duration of White Blood Cell (WBC) Count <10 x 10^9/L | 6.5 (0.0 to 18.2) |
Thrombotic events are defined as: new or recurrent acute myocardial infarction; unstable angina; stroke; transient ischemic attack (TIA); deep venous thrombosis (DVT); pulmonary embolism (PE); thrombotic digital ischemia; other thrombotic events such as peripheral limb ischemia or Budd-Chiari syndrome that are assessed to be due to underlying polycythemia vera (PV); other vascular occlusive events such as symptoms of cardiac, abdominal or peripheral limb ischemia supported by objective evidence of vessel disease and/or ischemia. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with thrombotic events are reported.
| Participants | Bomedemstat |
|---|---|
| Number of Participants With Thrombotic Events | 0 |
Hemorrhagic events were defined as: Major Bleeding (MB) Events such as fatal bleeding, and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells; Clinically Relevant Non-Major Bleeding (CRNMB) Events Leading to hospitalization or increased level of care or clinically important, prompting a face-to-face medical evaluation. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with major hemorrhagic events are reported.
| Participants | Bomedemstat |
|---|---|
| Number of Participants With Major Hemorrhagic Events | 1 |
Spleen volume was measured by magnetic resonance imaging (MRI) (or computerized tomography \[CT\] if participant is not a candidate for MRI) of the abdomen according to standard procedures. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with an enlarged spleen at baseline (volume \>450 cm\^3) who achieved any reduction in spleen volume by Week 36 are reported.
| Participants | Bomedemstat |
|---|---|
| Number of Participants With an Enlarged Spleen at Baseline Who Had a Reduction in Splenic Volume by 36 Weeks | 6 |
PD was defined as the worsening of Polycythemia Vera (PV) to post-PV myelofibrosis, myelodysplastic syndrome or transformation to acute myeloid leukemia. Baseline data was defined as the data most recently collected prior to the first dose. The number of participants with PD are reported.
| Participants | Bomedemstat |
|---|---|
| Number of Participants With Progressive Disease (PD) | 1 |
Collected over Up to approximately 22 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bomedemstat | 1/20 (5%) | 8/20 (40%) | 20/20 (100%) |
| Event | Bomedemstat |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/20 |
| Cardiac failureCardiac disorders | 1/20 |
| VertigoEar and labyrinth disorders | 1/20 |
| DiverticulitisInfections and infestations | 1/20 |
| Osteomyelitis acuteInfections and infestations | 1/20 |
| Wound infectionInfections and infestations | 1/20 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/20 |
| EncephalopathyNervous system disorders | 1/20 |
| Haemorrhagic strokeNervous system disorders | 1/20 |
| HeadacheNervous system disorders | 1/20 |
| Event | Bomedemstat |
|---|---|
| ConstipationGastrointestinal disorders | 9/20 |
| DiarrhoeaGastrointestinal disorders | 8/20 |
| FatigueGeneral disorders | 8/20 |
| DysgeusiaNervous system disorders | 8/20 |
| NauseaGastrointestinal disorders | 7/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/20 |
| ContusionInjury, poisoning and procedural complications | 6/20 |
| PruritusSkin and subcutaneous tissue disorders | 6/20 |
| Abdominal painGastrointestinal disorders | 5/20 |
| HeadacheNervous system disorders | 5/20 |
| Age, Continuous(Years) | Bomedemstat |
|---|---|
| Mean | 65.0 ± 12.5 |
| Sex: Female, Male(Participants) | Bomedemstat |
|---|---|
| Female | 5 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Bomedemstat |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Bomedemstat |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 20 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Mean Hematocrit Counts at Baseline(Percentage) | Bomedemstat |
|---|---|
| Mean | 43.99 ± 4.27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2023 to primary completion in Mar 2025, 18 months.
Results were first posted in May 2026, 1 year 1 month after primary completion.
Of 44 phase 2 interventional studies under Polycythemia Vera, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 135. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bomedemstat
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) →